Challenges and Prospects of Adoptive Immunotherapy in Prevention and Treatment of Opportunistic Mycoses in Hematologic Transplant Recipients

2010 ◽  
Vol 12 (6) ◽  
pp. 444-449 ◽  
Author(s):  
Lars Tramsen ◽  
Stanislaw Schmidt ◽  
Frauke Roeger ◽  
Ulrike Koehl ◽  
Thomas Lehrnbecher
Keyword(s):  
Adoptive Immunotherapy ◽  
Transplant Recipients ◽  
Prevention And Treatment ◽  
Opportunistic Mycoses

Cytomegalovirus in Solid Organ Transplant Recipients: Clinical Updates, Challenges and Future Directions

2020 ◽  
Vol 26 (28) ◽  
pp. 3497-3506
Author(s):  
Raymund R. Razonable
Keyword(s):  
Organ Transplantation ◽  
Solid Organ Transplantation ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Cmv Infection ◽  
Future Directions ◽  
Prevention And Treatment ◽  
Solid Organ Transplant Recipients

Cytomegalovirus is the classic opportunistic infection after solid organ transplantation. This review will discuss updates and future directions in the diagnosis, prevention and treatment of CMV infection in solid organ transplant recipients. Antiviral prophylaxis and pre-emptive therapy are the mainstays of CMV prevention, but they should not be mutually exclusive and each strategy should be considered depending on a specific situation. The lack of a widely applicable viral load threshold for diagnosis and preemptive therapy is emphasized as a major factor that should pave the way for an individualized approach to prevention. Valganciclovir and intravenous ganciclovir remain as drugs of choice for CMV management, and strategies for managing drug-resistant CMV infection are enumerated. There is increasing use of CMV-specific cell-mediated immune assays to stratify the risk of CMV infection after solid organ transplantation, and their potential role in optimizing CMV prevention and treatment efforts is discussed.

scholarly journals CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients

2020 ◽  
Author(s):  
Leila Amini ◽  
Dimitrios Laurin Wagner ◽  
Uta Rössler ◽  
Ghazaleh Zarrinrad ◽  
Livia Felicitas Wagner ◽  
...  
Keyword(s):  
T Cells ◽  
Adoptive Immunotherapy ◽  
Transplant Recipients ◽  
Antiviral T Cells

scholarly journals Hypertension in cardiac transplant recipients

2017 ◽  
Vol 19 (2) ◽  
pp. 114-125
Author(s):  
A. O. Shevchenko ◽  
E. A. Nikitina ◽  
I. Yu. Tunyaeva
Keyword(s):  
Blood Pressure ◽  
Renal Failure ◽  
Graft Failure ◽  
Great Majority ◽  
Premature Death ◽  
Cardiac Transplant ◽  
Elevated Blood ◽  
Transplant Recipients ◽  
Prevention And Treatment ◽  
Cardiac Graft

Hypertension is a common syndrome in adult and pediatric cardiac transplant recipients affecting the great majority of patients. Elevated blood pressure is a major potentially modifiable risk factor associated with cardiac graft failure, vasculopathy, arrhythmias, stroke, renal failure and premature death. This review discusses the magnitude of the problem, its distinct mechanisms, and certain issues of prevention and treatment of post-transplant hypertension.

scholarly journals Cancer Prevention and Treatment with Immune System Boosting Interventions

2019 ◽  
Author(s):  
Mohan Doss
Keyword(s):  
Clinical Trials ◽  
Immune System ◽  
Cancer Prevention ◽  
Organ Transplant ◽  
Transplant Recipients ◽  
Critical Levels ◽  
The World ◽  
Prevention And Treatment ◽  
Major Reduction ◽  
Critical Aspects

Cancer risk is known to increase tremendously when the immune system is suppressed, e.g., as observed in young organ-transplant recipients and AIDS patients. Based on such data, it may be hypothesized that the main reason for the development of clinical cancer is the weakening or suppression of the immune system, and that uncontrolled multiplication of cancer cells occurs when some aspects of the immune system fall below certain critical levels. Therefore, cancer may be prevented and treated by boosting these critical aspects of the immune system so that they are maintained above the critical levels. If multiple immune system boosting interventions are utilized, more aspects of the immune system would be boosted, increasing the likelihood of enhancing the critical aspects of the immune system and generating a cancer preventive and/or therapeutic effect. Clinical trials are needed to validate this approach for cancer prevention and treatment. If validated, the proposed approach could result in a major reduction of the death and suffering caused by cancer in the world.

Sign in / Sign up

Export Citation Format

Share Document